source
- Novartis reports positive multiple sclerosis results with its BTK inhibitorNovartis announced that its BTK inhibitor has shown a positive outcome in a multiple sclerosis study, marking a notable advance for the company in this therapeutic area. The result highlights the…
- Novartis' Rhapsido shows safety edge and relapse reduction in Phase 3 multiple sclerosis trialsNovartis reported results from two identical Phase 3 studies of its BTK inhibitor Rhapsido in patients with multiple sclerosis. The trials showed the oral pill lowered the annualized relapse rate…